Back to Search Start Over

Genotype-Phenotype Correlations and Characterization of Medication Use in Inherited Myotonic Disorders.

Authors :
Meyer AP
Roggenbuck J
LoRusso S
Kissel J
Smith RM
Kline D
Arnold WD
Source :
Frontiers in neurology [Front Neurol] 2020 Jun 26; Vol. 11, pp. 593. Date of Electronic Publication: 2020 Jun 26 (Print Publication: 2020).
Publication Year :
2020

Abstract

Introduction: Inherited myotonic disorders are genetically heterogeneous and associated with overlapping clinical features of muscle stiffness, weakness, and pain. Data on genotype-phenotype correlations are limited. In this study, clinical features and treatment patterns in genetically characterized myotonic disorders were compared. Methods: A retrospective chart review was completed in patients with genetic variants in CLCN1, SCN4A, DMPK , and CNBP to document clinical signs and symptoms, clinical testing, and antimyotonia medication use. Results: A total of 142 patients (27 CLCN1 , 15 SCN4A , 89 DMPK , and 11 CNBP ) were reviewed. The frequency of reported symptoms (stiffness, weakness, and pain) and electromyographic spontaneous activity were remarkably similar across genotypes. Most patients were not treated with antimyotonia agents, but those with non-dystrophic disorders were more likely to be on a treatment. Discussion: Among the features reviewed, we did not identify clinical or electrophysiological differences to distinguish CLCN1 - and SCN4A -related myotonia. Weakness and pain were more prevalent in non-dystrophic disorders than previously identified. In addition, our results suggest that medical treatments in myotonic disorders may be under-utilized.<br /> (Copyright © 2020 Meyer, Roggenbuck, LoRusso, Kissel, Smith, Kline and Arnold.)

Details

Language :
English
ISSN :
1664-2295
Volume :
11
Database :
MEDLINE
Journal :
Frontiers in neurology
Publication Type :
Academic Journal
Accession number :
32670189
Full Text :
https://doi.org/10.3389/fneur.2020.00593